openPR Logo
Press release

Fibroblast Activation Protein Inhibitors Market to Witness a Pronounce Growth by 2024

08-29-2018 09:38 AM CET | Health & Medicine

Press release from: Transparency Market Research 

Fibroblast Activation Protein Inhibitors Market to Witness

Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed on stromal fibroblasts of epithelial cancer cells and promotes cancer cell growth and metastasis.

View Report: https://www.transparencymarketresearch.com/fibroblast-activation-protein-inhibitors-market.html

The specificity of fibroblast activation protein offers potential to represent as a new drug target in the diagnosis and treatment of cancer. Various clinical trials are being conducted to assess the potential of treating cancer by inhibiting the fibroblast activation protein. Cancer cells are often very sensitive to growth factors. Development of cancer growth impeders such as fibroblast activation protein (FAP) inhibitors can provide promising results in cancer management.

Fibroblast activation protein (FAP) have similar specificity as dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP) which are also known to elevate in cancers. This leads to the need of development of inhibitors that are specific to fibroblast activation protein (FAP).

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14159

Huge opportunities lie in development of fibroblast activation protein (FAP) specific inhibitors. Vigorous research and development programs are being conducted for the development of such inhibitors. One such inhibitor is Val-boroPro (Talabostat) which is a single-agent inhibitor of fibroblast activation protein (FAP) enzymatic activity. A number of clinical trials have been conducted to assess the efficacy of talabostat as fibroblast activation protein (FAP) inhibitor in different cancers such as colorectal, lung, pancreatic, leukemia and melanoma. Another approach being used in developing fibroblast activation protein (FAP) inhibitor is monoclonal antibodies. However, such approaches have not been extensively used in the clinical setting, mainly due to absence of effective actions.

Due to the rise in the prevalence of cancer globally, fibroblast activation protein (FAP) inhibitors are anticipated to assist in prevention of proliferation of these carcinogenic cells. According to the National Cancer Institute, an estimated 1,685,210 new cases of cancer will be detected in 2016 in the U.S alone. The most common ones are breast cancer, prostate cancer, colon and rectum cancer, lung and bronchus cancer, bladder cancer, melanoma, kidney and renal pelvis cancer, leukemia, and pancreatic cancer. Of these colorectal cancer is the third most common type of cancer in the world. This cancer is a result of uninhibited cell progression that occurs in the appendix, colon, and the rectum region. The common symptoms of colorectal cancer are bleeding in the stool, weight loss, fatigue, and irregular bowel movements. According to the World Cancer Research Fund International, approximately 1.5 million new cases of colorectal cancer are detected each year. Many clinical trials are being conducted to discover novel methods to treat colorectal cancer through fibroblast activation protein (FAP) inhibitors.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14159

The increasing worldwide prevalence of various cancers, including breast cancer, colorectal cancer, prostate cancer, skin cancer, blood cancer, gastrointestinal tract cancer, and lung cancer, is the prime factor heightening the demand for anti-cancer drugs. In addition to this, the improvement of advanced therapeutic approaches, such as targeted therapies, immunotherapy, radiotherapy, and chemotherapy has significantly benefited the anti-cancer drugs market in recent years. Although not much progress has been made in fibroblast activation protein (FAP) inhibitors discovery for treating various cancer, this field possesses huge research and development opportunities in the near future.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fibroblast Activation Protein Inhibitors Market to Witness a Pronounce Growth by 2024 here

News-ID: 1208391 • Views: 108

More Releases from Transparency Market Research 

Image Guided Surgery Devices Market Analysis and Research Report by Experts 2025
The global image guided surgery devices market is directly reliant on the development of healthcare across various regional longitudes of the world. As the healthcare industry make rapid advancements across a number of its sub-domains, the market for global image guided surgery devices would see the entry of new players into the market. The competition is expected to intensify in the coming years and wreak the need for proper strategizing
Laboratory Centrifuge Market Growth, Trends and Demands Research Report and Fore …
The players in the worldwide laboratory centrifuge market are concentrating on item launch with a technological distinction. The focused scene is broadly divided because of solid emergence of a few players. Organizations are likewise foreseen that they would concentrate on clinical trials, joint ventures, research and development, mergers, and acquisitions to stay in ahead of the opposition. A portion of the main players in the worldwide laboratory centrifuge market are
Surgical Drapes Market Competitive Strategies, Regional Analysis Forecast 2024
The global surgical drapes market exhibit the presence of several tier 1, tier 2, and tier 3 companies. This is indicative of a highly competitive vendor landscape. According to a new study by Transparency Market Research (TMR), some of the prominent companies operating in the global surgical drapes market have resorted to strategies such as product differentiation, aggressive pricing, and product upgrades to buoy competitive strength. Besides these, several companies
Heparin Market Precise Analysis on Business Overview, Product Scope And Ongoing …
The global heparin market is expected to become progressively competitive over the forthcoming years. This is due to the strengthening position of the leading market players in the global market for heparin. Several initiatives have been taken by the leading market players to retain their strong foothold over the market. Intensive research and development along with effective marketing hacks have been the key highlights of the business strategy of the

All 5 Releases


More Releases for FAP

Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Fibroblast Activation Protein Inhibitors Market Dynamics, Forecast, Analysis and …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market with Current Trends Analysis, 20 …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market by Key Players, Growth, Regions …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
01-25-2017 | Health & Medicine
TMR
Fibroblast Activation Protein Inhibitors Market - Evolving Technology, Trends an …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market : Huge Opportunities Lie In Deve …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed